PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Clin Neurosci. Author manuscript; available in PMC 2013 September 30.
Published in final edited form as:
PMCID: PMC3786731
NIHMSID: NIHMS160364

The Role of Microglia in Central Nervous System Immunity and Glioma Immunology

Abstract

The central nervous system (CNS) historically has been considered an immune-privileged organ, lacking a lymphatic system and shielded from the circulatory system by the blood-brain barrier. Microglia are an abundant portion of the CNS cell population, comprising 5% to 20% of the total glial cell population, and are as numerous as neurons. A crucial function of microglia is the ability to generate significant innate and adaptive immune responses. Microglia are involved in first line innate immunity of the CNS. Proper antigen presentation is critical in the generation of specific, durable responses by the adaptive immune system, and requires interaction between the T cell receptor and processed antigen peptide presented on major histocompatibility complex (MHC) molecules by the antigen presenting cells. Microglia also have a large regulatory role in CNS immunity. Histopathologic studies of glioma tissue have consistently shown high levels of infiltrating microglia. Microglia are also localized diffusely throughout the tumor, rather than to the areas of necrosis, and phagocytosis of glioma cells or debris by microglia is not observed. Recent evidence indicates that glioma-infiltrating microglia/macrophages might be promoting tumor growth by facilitating immunosuppression of the tumor microenvironment. When activated, microglia can be potent immune effector cells, able to perform a broad range of functions, and they mediate both innate and adaptive responses during CNS injury and disease while remaining quiescent in the steady state. Their versatility in bridging the gap between the immune-privileged CNS and the peripheral immune system, in addition to their significant numbers in gliomas, makes them an attractive candidate in immunotherapy for gliomas. An enhanced understanding of microglia–glioma interaction can provide better methods to manipulate the glioma microenvironment to allow the generation of a specific and durable anti-glioma immunity. The role of microglia in CNS immunity is discussed, with a focus on key advances made in glioma immunology.

Keywords: Antigen presenting cells, Gliomas, Immunology, Immunotherapy, Innate immunity, Microglia, Specific immunity

1. Introduction

The central nervous system (CNS) historically has been considered an immune-privileged organ, lacking a lymphatic system and shielded from the circulatory system by the blood-brain barrier. Thus, the CNS is isolated from entry of most peripheral immune cells, soluble factors and plasma proteins. However, the infiltration of T lymphocytes and antigen presenting cells (APC) during a variety of CNS pathologies, such as multiple sclerosis and glioma [1, 2], is evidence for an adapted system of immunosurveillance with coordination with the systemic immune system. As resident APCs and macrophages, microglia are in the key position for coordinating this system of active surveillance.

Through intimate relationships with the surrounding microenvironment, microglia maintain a quiescent phenotype in the normal CNS, expressing low levels of major histocompatibility complex (MHC) class I and class II molecules as well as costimulatory molecules such as CD86 and CD40 [37]. In the context of CNS insult or injury, microglia convert to an active phenotype, with increased proliferation [8], motility [9], and phagocytic activity [10, 11], and release cytokines and reactive oxygen species [12]. As activated APCs, microglia have similar roles to macrophages in peripheral tissues, serving as essential components of both the innate and adaptive immune responses. Upon activation, microglia upregulate both MHC and costimulatory molecules, and contribute to both CD4-specific and CD8-specific T cell responses [1315]. Microglia, in addition to lymphocytes, have also been found in CNS disease processes, including tumors of the CNS [16]. In this review, we focus on the recent and key advances in understanding the role of microglia in CNS immunity and glioma immunology.

2. Origin of Microglia

Microglia are an abundant portion of the CNS cell population, comprising 5% to 20% of the total glial cell population, and are as numerous as neurons [1719]. Nissl first described microglia, naming them “Staebchenzellen” or rod cells based on the shape of nuclei. He considered microglia as reactive neuroglia, hinting at their capacity for migration and phagocytosis. They were subsequently characterized by Santiago Ramon y Cajal in 1913 as part of three elements of the CNS and by del Rio Hortega, who recognized microglia as a cell type distinct from other glial cell populations. By studying the results of stab wounds made in animal brains, Hortega observed and accurately described that microglia cells can transform from a resting ramified form into amoeboid phagocytic macrophages [20]. From these findings, he proposed that microglia originated from peripheral mononuclear cells [20].

After a long debate over the role and origin of microglia, they have been established as a developmentally and functionally distinct population of glial cells that are of myelomonocytic origin [21]. Circulating microglia precursors derived from mesodermal hematopoietic cells enter the developing brain during perinatal stages and transform into microglia cells. Mature microglia express a variety of macrophage-specific markers including Toll-like receptors (TLR) [22, 23], the integrin CD11b [24], and the glycoprotein of unknown function, F4/80. However, they have lower levels of leukocyte common antigen, CD45, when compared to macrophages [25, 26]. Thus, microglia are closely related to peripheral monocytes in regard to their origins, phagocytic activity, and surface markers.

Microglia are classified according their morphology into three types: resting ramified, activated, and amoeboid phagocytic [21]. In the perinatal brain, the amoeboid phagocytic microglia are the predominant form [27]. During postnatal maturation, amoeboid microglia transform into ramified resting microglia, and these cells remain a semi-permanent population with relatively slow turnover rates when compared to peripheral macrophages [27, 28]. As resting ramified microglia, they monitor their microenvironment and adapt their morphology and expressed cell surface markers accordingly [18, 19]. They remain quiescent until stimuli from injury, infection or neurodegenerative process activate their transformation into amoeboid phagocytic cells [10, 11].

3. Active Surveillance of the Central Nervous System

As routine surveillance of the CNS, microglia, even in their quiescent form, continually monitor their microenvironment through pinocytosis and interaction with neurons [29]. A complex set of interactions exist between local stimulatory and inhibitory signals in shaping microglial responses: while some neurotransmitters like substance P enhance the active phenotype of microglia [30], electrically active neurons inhibit the increase in expression of MHC class II molecules on microglia in response to Th1 cytokine interferon-gamma (IFN-γ) [31]. In addition, Hoek and colleagues have implicated a membrane-bound glycoprotein, OX2 or CD200, expressed on neurons as a key regulator of microglia [32, 33]. The authors showed that microglia in OX2-deficient mice exhibit a constitutively active phenotype with increased subset with amoeboid phagocytic morphology, and elevated levels of expression of CD45 and complement type-3 receptor (CR3) [32]. OX2-deficient mice also show an accelerated reactive response to CNS injury.

Moreover, soluble factors in the microenvironment influence the functional and morphological plasticity and activity of microglia as well. Granulocyte-macrophage colony stimulating factor (GM-CSF) and macrophage-CSF (M-CSF) have crucial roles in the terminal differentiation of tissue macrophages. In Alzheimer’s disease and multiple sclerosis, levels of GM-CSF are elevated in addition to upregulation in M-CSF receptors [34]. Fischer and Reichmann have demonstrated that in vitro incubation of purified microglia with GM-CSF increases microglia cell size and induces a heterogeneous population that contains cells resembling other tissue macrophages [35]. These populations of microglial cells take on APC activity by expression of MHC class II molecules [25].

These findings in combination provide strong support for microenvironmental regulation of microglia function, through soluble factors, such as GM-CSF and M-CSF, and cell–cell interactions, particularly with neurons, which have key roles in delivery of regulatory signals, in part through the glycoprotein OX-2.

4. Microglia as Mediators of Inflammation

A crucial functional similarity of microglia to peripheral macrophages is the ability to generate significant innate and adaptive immune responses. The resting ramified microglia cells are activated by a variety of CNS pathologies, such as infection, injury, and neurodegenerative disease, by detecting lipopolysaccharide (LPS), beta-amyloid (Aβ), thrombin, IFN-γ, and other proinflammatory cytokines [36]. For example, microglia express TLR [22] and initiate innate responses with the production of cytokines, chemokines and nitric oxide (NO) [37, 38]. Specifically, cytokines released by activated microglia include interleukin (IL)-1 [39], IL-6 [40] and tumor necrosis factor-alpha (TNF-α) [41], as well as monocyte chemoattractant protein-1 (MCP-1) [42], macrophage inflammatory protein-1 [43, 44] and RANTES [45], and chemokines for lymphocyte recruitment. These results show that microglia are involved in first line innate immunity of the CNS. Once the microenvironment of the CNS becomes activated, local cells also produce proinflammatory cytokines, chemokines and upregulate immunomodulatory surface markers. These changes in turn decrease the stringency of the blood-brain barrier, allowing entry of soluble factors and peripheral immune cells [46], including macrophages, natural killer cells and lymphocytes [47, 48]. The specific sequence of events demonstrating that microglia activation precedes peripheral cell infiltration has been demonstrated in bone marrow chimeric mice in an elegant study by Schilling and colleagues [49].

Phagocytic and cytotoxic functions of microglia are also triggered during CNS injury. Upon activation, microglia upregulate opsonic receptors including complement receptors (CR1, CR3, CR4) and Fc gamma receptors (I, II, III), which enhance phagocytic activity by binding to complement components and immunoglobulin fragments respectively [50, 51]. Microglia also show transitory phagocytosis during CNS ontogeny to clear apoptotic neuronal cell bodies [52]. A similar phenomenon is seen in animal models of multiple sclerosis – T cell debris undergoes phagocytosis by microglia [53]. Contents that undergo phagocytosis by microglia are degraded by the immediate induction to produce reactive radicals. In addition, the cytotoxic functions of microglia are carried out by release of superoxide radicals and NO into the microenvironment in response to pathogens and cytokine stimulation [54].

Proper antigen presentation is critical in the generation-specific durable responses by the adaptive immune system, and requires interaction between the T cell receptor and processed antigen peptide presented on MHC molecules by the APCs. The presentation is augmented by interaction between costimulatory molecules such as B7.1, CD40, CD80, and CD86 expressed on the surface of APC and specific counter-receptors on T cells [55, 56]. Within the CNS under resting states, MHC class I and II expression is generally absent or minimally present [3, 57]. MHC molecules are generally restricted to microglia in low levels [6, 57, 58]. Resting microglia serve as poor APC [59]; however, activating stimuli induce microglia to robustly increase their expression of MHC [60] and costimulatory molecules [61]. Costimulatory molecules CD80 and CD86 on microglia in turn bind to CD28 expressed on T cells to induce cytokine secretion and proliferation by T cells [55]. CD40L on T cells in turn interact with CD40 of microglia and increase the expression of CD80 and CD86 MHC class II molecules [56]. The CD40–CD40L interaction also induces microglia to increase the release of nitric synthase [56]. Additionally, in vivo and in vitro studies have demonstrated that IFN-γ induces and maintains expression of MHC class II and adhesion/costimulatory molecules on microglia to maintain T cell stimulation [62]. This cooperative enhancement of costimulation between microglia and T cells has been demonstrated in animal models of multiple sclerosis [34].

Microglia also have a large regulatory role in CNS immunity. In the absence of sufficient costimulatory molecules, the interaction of Fas ligand (FASL) on microglia and Fas receptor on the T cell leads to activation-induced T cell apoptosis [63]. The FASL expression on microglia has been described in vitro [64, 65] and in mouse models of multiple sclerosis [66]. Microglia in turn also express FAS molecules which, upon binding FASL, leads to their own apoptosis [66]. In addition, cytotoxic molecules like NO produced by microglia can also contribute to the death of immune effector responses. Hence, microglia activation can be self-limiting and microglia have regulatory functions in silencing other immune effector cells.

5. Microglia in Glioma Immunology

In 1925, Wilder Penfield, employing the same silver staining method used by Rio-Hortega, provided the first detailed descriptions of microglia in glioma tissue [20]. Subsequently, gliomas have been shown to accumulate many microglia along with a small population of lymphocytes [16]. Initially, the observation that malignant gliomas contain particularly high levels of microglia infiltrates led to the hypothesis that microglia may contain anti-tumor activity and have a role in tumor necrosis. However, recent evidence strongly supports that microglia contribute to the immunosuppressive environment of gliomas and may promote tumor proliferation and progression [16, 6770].

5.1. Microglia chemoattraction and proliferation

Histopathologic studies of glioma tissue have consistently shown high levels of infiltrating microglia [2, 7174]. Flow cytometry studies by Badie and colleagues demonstrated that as many as one-third of cells of glioma tissues express resident microglia markers, consisting of the largest population of immune cells [2]. Current evidence supports that the accumulation of microglia in glioma is due to local production chemoattractants and growth factors by glioma cells. MCP-1 is produced by glioma cells, and microglia express a specific MCP-1 receptor, CCR2 [75, 76]. Furthermore, growth factors known to induce macrophage/microglia proliferation, such as CSF-1, G-CSF and hepatocyte growth factor/scatter factor (HGF/SF) are also secreted by various gliomas [7779].

5.2. Microglia and glioma progression

Historically, the recruitment of microglia in gliomas was postulated as evidence of the attempt by CNS to fend off dividing neoplastic cells [80]. However, the paradox of continuing aggressive tumor growth despite high levels of microglia infiltrates offered little support for anti-glioma activity of these microglia. Microglia are also localized diffusely throughout the tumor, and not to the areas of necrosis, and phagocytosis of glioma cells or debris by microglia is not observed [1]. Recent evidence indicates that glioma-infiltrating microglia/macrophages might be promoting tumor growth by facilitating immunosuppression of the tumor microenvironment [16].

Microglia are a cellular source of matrix metalloproteases-2, extracellular matrix-degrading enzymes. Their release into the tumor environment can help increase the spread of tumors by paving the road for proliferation of tumor cells [81]. Microglia also secrete tumor proliferation promoting factors including epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) [82, 83]. These studies in combination suggest that microglia have an integrative role in the tumor progression by supporting migration (MMP-9), angiogenesis (VEGF), and proliferation (EGF) of glioma cells.

5.3. Inhibited microglia function in glioma

Co-culture of human peripheral blood mononuclear cells with human glioma lines caused glioma-conditioned monocytes to reduce phagocytic activity [84]. The glioma–monocyte co-culture, but not monocyte in isolation, also induced apoptosis of activated lymphocytes [84]. Although MHC molecule expression is seen on microglia within glioma tissues [85, 86], they appear deficient in proper antigen presentation [87] for cytotoxic and helper T cell activation. The number of microglia cells expressing MHC class II antigen is reduced even further in high grade gliomas despite the high abundance of microglia present. Schartner and colleagues demonstrated that glioma infiltrating microglia isolated from mice do not show MHC class II upregulation following stimulation [67]. In contrast, the expressions of MHC class II and costimulatory B7 molecules were significantly increased when freshly isolated microglia were cultured in the absence of glioma cells [88].

Kostianovsky and colleagues demonstrated in vitro that glioblastoma cells down regulated the production of the proinflammatory cytokine TNF-α by microglia when stimulated with LPS or β-amyloid [70]. Instead, the stimulation resulted in the secretion of IL-10 an anti-inflammatory cytokine by the microglia [70]. IL-10 in turn inhibits cytotoxic T cell function, further contributing to the immunoresistant phenotype of glioma cells [89]. IL-10 also suppresses function of microglia: in vitro studies demonstrated that IL-10 suppresses IFN-γ induced MHC class II expression [90]. These studies together suggest that phagocytosis, antigen presentation, and secretion of proinflammatory cytokines are strongly suppressed by glioma cells.

5.4. Microglia and local immune suppression by glioma

Glioma cells produce anti-inflammatory cytokines such as IL-6 and TGF-β2 and PGE2 along with producing tumor growth promoting cytokines such as IL-1 and bFGF [1, 91]. In particular, TGF-β2 inhibits proliferation and secretion of proinflammatory cytokines by microglia and lymphocytes [92]. In normal brain, microglia express B7-H1, a potent immunosuppressive molecule that induces T cell apoptosis [93, 94]. In addition to increased expression of B7-H1 in a subset of gliomas with immunoresistant phenotypes, the expression of B7-H1 is upregulated in microglia found in glioma [9395]. FASL is another inhibitory molecule expressed on tumor-associated microglia that might be crucial in limiting the ability of T cells to recognize and respond to tumor cells. FASL also induces T cell apoptosis, particularly of CD8+ cytotoxic T cells. Microglia in intracranial tumors express FASL and inhibition of FASL leads to a dramatic increase in the number of peripheral immune effector cells seen within tumors [69, 96].

5.5. Therapeutic potential of microglia in glioma

When activated, microglia are potent immune effector cells, able to perform a broad range of functions, and they mediate both innate and adaptive responses during CNS injury and disease while remaining quiescent in the steady state. Their versatility in bridging the gap between the immune-privileged CNS and the peripheral immune system in addition to their significant numbers in gliomas makes them an attractive candidate in immunotherapy for gliomas. Unfortunately, microglia associated with malignant gliomas appear incapable of inducing an effective anti-tumor T cell response. If glioma-induced immunosuppression of microglia function could be overcome, CNS immunity against tumors can be significantly enhanced. For example, Carpentier and colleagues demonstrated long-term survival in animals with glioma using single intratumoral injection of CpG oligodeoxynucleotide, an immuno-stimulatory sequence that signals through TLR9 to induce the production of IFN-α, IFN-β, IL-12, and TNF-α [97, 98]. However, animals depleted of macrophage/microglia were unable to reject the tumor after CpG treatment, showing that microglia/macrophages are critical components of an anti-tumor response [99]. Although CpG is relatively safe in humans, an enhanced understanding of the microglia–glioma interaction can provide better methods to manipulate the glioma microenvironment to allow the generation of a specific and durable anti-glioma immunity.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Hao C, I, Parney F, Roa WH, et al. Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol (Berl) 2002;103(2):171–8. [PubMed]
2. Badie B, Schartner JM, Paul J, et al. Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg. 2000;93(4):634–9. [PubMed]
3. Yang I, Kremen TJ, Giovannone AJ, et al. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg. 2004;100(2):310–9. [PubMed]
4. Aloisi F, De Simone R, Columba-Cabezas S, et al. Functional maturation of adult mouse resting microglia into an APC is promoted by granulocyte-macrophage colony-stimulating factor and interaction with Th1 cells. J Immunol. 2000;164(4):1705–12. [PubMed]
5. Ayoub AE, Salm AK. Increased morphological diversity of microglia in the activated hypothalamic supraoptic nucleus. J Neurosci. 2003;23(21):7759–66. [PubMed]
6. Hoftberger R, Aboul-Enein F, Brueck W, et al. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 2004;14(1):43–50. [PubMed]
7. Sedgwick JD, Schwender S, Imrich H, et al. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci U S A. 1991;88(16):7438–42. [PubMed]
8. Eliason DA, Cohen SA, Baratta J, et al. Local proliferation of microglia cells in response to neocortical injury in vitro. Brain Res Dev Brain Res. 2002;137(1):75–9. [PubMed]
9. Carbonell WS, Murase SI, Horwitz AF, et al. Infiltrative microgliosis: activation and long-distance migration of subependymal microglia following periventricular insults. J Neuroinflammation. 2005;2(1):5. [PMC free article] [PubMed]
10. Schroeter M, Jander S, Huitinga I, et al. Phagocytic response in photochemically induced infarction of rat cerebral cortex. The role of resident microglia. Stroke. 1997;28(2):382–6. [PubMed]
11. Zhang SC, Goetz BD, Carre JL, et al. Reactive microglia in dysmyelination and demyelination. Glia. 2001;34(2):101–9. [PubMed]
12. Liu L, Persson JK, Svensson M, et al. Glial cell responses, complement, and clusterin in the central nervous system following dorsal root transection. Glia. 1998;23(3):221–38. [PubMed]
13. Aloisi F, Ria F, Columba-Cabezas S, et al. Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naive CD4+ T cell priming and Th1/Th2 cell restimulation. Eur J Immunol. 1999;29(9):2705–14. [PubMed]
14. Aloisi F, Ria F, Penna G, et al. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J Immunol. 1998;160(10):4671–80. [PubMed]
15. Brannan CA, Roberts MR. Resident microglia from adult mice are refractory to nitric oxide-inducing stimuli due to impaired NOS2 gene expression. Glia. 2004;48(2):120–31. [PubMed]
16. Badie B, Schartner J. Role of microglia in glioma biology. Microsc Res Tech. 2001;54(2):106–13. [PubMed]
17. Benveniste EN. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med. 1997;75(3):165–73. [PubMed]
18. Lawson LJ, V, Perry H, Dri P, et al. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990;39(1):151–70. [PubMed]
19. Lawson LJ, V, Perry H, Gordon S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience. 1992;48(2):405–15. [PubMed]
20. Del Rio-Hortega P, Penfield W, editors. Cytology and Cellular Pathology of the Nervous System. 11. Paul B Hoeber; New York: 1932. Microglia; pp. 481–534.
21. Ling EA, Wong WC. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia. 1993;7(1):9–18. [PubMed]
22. Bsibsi M, Ravid R, Gveric D, et al. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol. 2002;61(11):1013–21. [PubMed]
23. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol. 2004;173(6):3916–24. [PubMed]
24. Akiyama H, McGeer PL. Brain microglia constitutively express beta-2 integrins. J Neuroimmunol. 1990;30(1):81–93. [PubMed]
25. Dick AD, Ford AL, Forrester JV, et al. Flow cytometric identification of a minority population of MHC class II positive cells in the normal rat retina distinct from CD45lowCD11b/c+CD4low parenchymal microglia. Br J Ophthalmol. 1995;79(9):834–40. [PMC free article] [PubMed]
26. Becher B, Antel JP. Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia. Glia. 1996;18(1):1–10. [PubMed]
27. Hess DC, Abe T, Hill WD, et al. Hematopoietic origin of microglial and perivascular cells in brain. Exp Neurol. 2004;186(2):134–44. [PubMed]
28. Kennedy DW, Abkowitz JL. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood. 1997;90(3):986–93. [PubMed]
29. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308(5726):1314–8. [PubMed]
30. McCluskey LP, Lampson LA. Local neurochemicals and site-specific immune regulation in the CNS. J Neuropathol Exp Neurol. 2000;59(3):177–87. [PubMed]
31. Neumann H, Boucraut J, Hahnel C, et al. Neuronal control of MHC class II inducibility in rat astrocytes and microglia. Eur J Neurosci. 1996;8(12):2582–90. [PubMed]
32. Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200) Science. 2000;290(5497):1768–71. [PubMed]
33. Wright GJ, Puklavec MJ, Willis AC, et al. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity. 2000;13(2):233–42. [PubMed]
34. Li H, Cuzner ML, Newcombe J. Microglia-derived macrophages in early multiple sclerosis plaques. Neuropathol Appl Neurobiol. 1996;22(3):207–15. [PubMed]
35. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol. 2001;166(4):2717–26. [PubMed]
36. Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. Curr Med Chem. 2007;14(11):1189–97. [PubMed]
37. Banati RB, Gehrmann J, Schubert P, et al. Cytotoxicity of microglia. Glia. 1993;7(1):111–8. [PubMed]
38. Nakamichi K, Saiki M, Sawada M, et al. Double-stranded RNA stimulates chemokine expression in microglia through vacuolar pH-dependent activation of intracellular signaling pathways. J Neurochem. 2005 [PubMed]
39. Hartlage-Rubsamen M, Lemke R, Schliebs R. Interleukin-1beta, inducible nitric oxide synthase, and nuclear factor-kappaB are induced in morphologically distinct microglia after rat hippocampal lipopolysaccharide/interferon-gamma injection. J Neurosci Res. 1999;57(3):388–98. [PubMed]
40. Suzumura A, Sawada M, Marunouchi T. Selective induction of interleukin-6 in mouse microglia by granulocyte-macrophage colony-stimulating factor. Brain Res. 1996;713(1–2):192–8. [PubMed]
41. Floden AM, Li S, Combs CK. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci. 2005;25(10):2566–75. [PubMed]
42. Babcock AA, Kuziel WA, Rivest S, et al. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci. 2003;23(21):7922–30. [PubMed]
43. Si Q, Cosenza M, Zhao ML, et al. GM-CSF and M-CSF modulate beta-chemokine and HIV-1 expression in microglia. Glia. 2002;39(2):174–83. [PubMed]
44. Takami S, Nishikawa H, Minami M, et al. Induction of macrophage inflammatory protein MIP-1alpha mRNA on glial cells after focal cerebral ischemia in the rat. Neurosci Lett. 1997;227(3):173–6. [PubMed]
45. Chen CJ, Chen JH, Chen SY, et al. Upregulation of RANTES gene expression in neuroglia by Japanese encephalitis virus infection. J Virol. 2004;78(22):12107–19. [PMC free article] [PubMed]
46. Lu J, Moochhala S, Kaur C, et al. Cellular inflammatory response associated with breakdown of the blood-brain barrier after closed head injury in rats. J Neurotrauma. 2001;18(4):399–408. [PubMed]
47. Tonra JR, Reiseter BS, Kolbeck R, et al. Comparison of the timing of acute blood-brain barrier breakdown to rabbit immunoglobulin G in the cerebellum and spinal cord of mice with experimental autoimmune encephalomyelitis. J Comp Neurol. 2001;430(1):131–44. [PubMed]
48. Baldwin AC, Kielian T. Persistent immune activation associated with a mouse model of Staphylococcus aureus-induced experimental brain abscess. J Neuroimmunol. 2004;151(1–2):24–32. [PubMed]
49. Schilling M, Besselmann M, Leonhard C, et al. Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol. 2003;183(1):25–33. [PubMed]
50. Peress NS, Fleit HB, Perillo E, et al. Identification of Fc gamma RI, II and III on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer’s disease. J Neuroimmunol. 1993;48(1):71–9. [PubMed]
51. Barnum SR. Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease. Mol Med. 1999;5(9):569–82. [PMC free article] [PubMed]
52. Ferrer I, Bernet E, Soriano E, et al. Naturally occurring cell death in the cerebral cortex of the rat and removal of dead cells by transitory phagocytes. Neuroscience. 1990;39(2):451–8. [PubMed]
53. Nguyen KB, Pender MP. Phagocytosis of apoptotic lymphocytes by oligodendrocytes in experimental autoimmune encephalomyelitis. Acta Neuropathol. 1998;95(1):40–6. [PubMed]
54. Chao CC, Hu S, Peterson PK. Modulation of human microglial cell superoxide production by cytokines. J Leukoc Biol. 1995;58(1):65–70. [PubMed]
55. Slavik JM, Hutchcroft JE, Bierer BE. CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol Res. 1999;19(1):1–24. [PubMed]
56. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67(1):2–17. [PubMed]
57. Stoll M, Capper D, Dietz K, et al. Differential microglial regulation in the human spinal cord under normal and pathological conditions. Neuropathol Appl Neurobiol. 2006;32(6):650–61. [PubMed]
58. Gehrmann J, Matsumoto Y, Kreutzberg GW. Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev. 1995;20(3):269–87. [PubMed]
59. Ford AL, Foulcher E, Lemckert FA, et al. Microglia induce CD4 T lymphocyte final effector function and death. J Exp Med. 1996;184(5):1737–45. [PMC free article] [PubMed]
60. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19(8):312–8. [PubMed]
61. De Simone R, Giampaolo A, Giometto B, et al. The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions. J Neuropathol Exp Neurol. 1995;54(2):175–87. [PubMed]
62. Shrikant P, Benveniste EN. The central nervous system as an immunocompetent organ: role of glial cells in antigen presentation. J Immunol. 1996;157(5):1819–22. [PubMed]
63. Pender MP, Rist MJ. Apoptosis of inflammatory cells in immune control of the nervous system: role of glia. Glia. 2001;36(2):137–44. [PubMed]
64. Spanaus KS, Schlapbach R, Fontana A. TNF-alpha and IFN-gamma render microglia sensitive to Fas ligand-induced apoptosis by induction of Fas expression and down-regulation of Bcl-2 and Bcl-xL. Eur J Immunol. 1998;28(12):4398–408. [PubMed]
65. Frigerio S, Silei V, Ciusani E, et al. Modulation of fas-ligand (Fas-L) on human microglial cells: an in vitro study. J Neuroimmunol. 2000;105(2):109–14. [PubMed]
66. Kohji T, Matsumoto Y. Coexpression of Fas/FasL and Bax on brain and infiltrating T cells in the central nervous system is closely associated with apoptotic cell death during autoimmune encephalomyelitis. J Neuroimmunol. 2000;106(1–2):165–71. [PubMed]
67. Schartner JM, Hagar AR, Van Handel M, et al. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia. 2005;51(4):279–85. [PubMed]
68. Bettinger I, Thanos S, Paulus W. Microglia promote glioma migration. Acta Neuropathol. 2002;103(4):351–5. [PubMed]
69. Badie B, Schartner J, Prabakaran S, et al. Expression of Fas ligand by microglia: possible role in glioma immune evasion. J Neuroimmunol. 2001;120(1–2):19–24. [PubMed]
70. Kostianovsky AM, Maier LM, Anderson RC, et al. Astrocytic regulation of human monocytic/microglial activation. J Immunol. 2008;181(8):5425–32. [PubMed]
71. Rossi ML, Jones NR, Candy E, et al. The mononuclear cell infiltrate compared with survival in high-grade astrocytomas. Acta Neuropathol. 1989;78(2):189–93. [PubMed]
72. Roggendorf W, Strupp S, Paulus W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol. 1996;92(3):288–93. [PubMed]
73. Streit WJ. Cellular immune response in brain tumors. Neuropathol Appl Neurobiol. 1994;20(2):205–6. [PubMed]
74. Wierzba-Bobrowicz T, Kuchna I, Matyja E. Reaction of microglial cells in human astrocytomas (preliminary report) Folia Neuropathol. 1994;32(4):251–2. [PubMed]
75. Prat E, Baron P, Meda L, et al. The human astrocytoma cell line U373MG produces monocyte chemotactic protein (MCP)-1 upon stimulation with beta-amyloid protein. Neurosci Lett. 2000;283(3):177–80. [PubMed]
76. Galasso JM, Stegman LD, Blaivas M, et al. Experimental gliosarcoma induces chemokine receptor expression in rat brain. Exp Neurol. 2000;161(1):85–95. [PubMed]
77. Suzuki Y, Funakoshi H, Machide M, et al. Regulation of cell migration and cytokine production by HGF-like protein (HLP)/macrophage stimulating protein (MSP) in primary microglia. Biomed Res. 2008;29(2):77–84. [PubMed]
78. Alterman RL, Stanley ER. Colony stimulating factor-1 expression in human glioma. Mol Chem Neuropathol. 1994;21(2–3):177–88. [PubMed]
79. Badie B, Schartner J, Klaver J, et al. In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. Neurosurgery. 1999;44(5):1077–82. discussion 1082–3. [PubMed]
80. Morantz RA, Wood GW, Foster M, et al. Macrophages in experimental and human brain tumors. Part 2: studies of the macrophage content of human brain tumors. J Neurosurg. 1979;50(3):305–11. [PubMed]
81. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003;3(7):489–501. [PubMed]
82. Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg. 1995;82(5):864–73. [PubMed]
83. Lafuente JV, Adan B, Alkiza K, et al. Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. J Mol Neurosci. 1999;13(1–2):177–85. [PubMed]
84. Parney IF, Waldron JS, Parsa AT. Flow cytometry and in vitro analysis of human glioma-associated macrophages. J Neurosurg. 2009 [PMC free article] [PubMed]
85. Proescholdt MA, Merrill MJ, Ikejiri B, et al. Site-specific immune response to implanted gliomas. J Neurosurg. 2001;95(6):1012–9. [PubMed]
86. Tran CT, Wolz P, Egensperger R, et al. Differential expression of MHC class II molecules by microglia and neoplastic astroglia: relevance for the escape of astrocytoma cells from immune surveillance. Neuropathol Appl Neurobiol. 1998;24(4):293–301. [PubMed]
87. Flugel A, Labeur MS, Grasbon-Frodl EM, et al. Microglia only weakly present glioma antigen to cytotoxic T cells. Int J Dev Neurosci. 1999;17(5–6):547–56. [PubMed]
88. Badie B, Bartley B, Schartner J. Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas. J Neuroimmunol. 2002;133(1–2):39–45. [PubMed]
89. Hishii M, Nitta T, Ishida H, et al. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery. 1995;37(6):1160–6. discussion 1166–7. [PubMed]
90. O’Keefe GM, V, Nguyen T, Benveniste EN. Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-beta, IL-4, IL-13 and IL-10. Eur J Immunol. 1999;29(4):1275–85. [PubMed]
91. Parney IF, Hao C, Petruk KC. Glioma immunology and immunotherapy. Neurosurgery. 2000;46(4):778–91. discussion 791–2. [PubMed]
92. Suzumura A, Sawada M, Yamamoto H, et al. Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. J Immunol. 1993;151(4):2150–8. [PubMed]
93. Magnus T, Schreiner B, Korn T, et al. Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci. 2005;25(10):2537–46. [PubMed]
94. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84–8. [PubMed]
95. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800. [PubMed]
96. Walker DG, Chuah T, Rist MJ, et al. T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy. J Neuroimmunol. 2006;175(1–2):59–68. [PubMed]
97. Carpentier AF, Xie J, Mokhtari K, et al. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res. 2000;6(6):2469–73. [PubMed]
98. Carpentier AF, Auf G, Delattre JY. CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma. Front Biosci. 2003;8:e115–27. [PubMed]
99. Auf G, Carpentier AF, Chen L, et al. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res. 2001;7(11):3540–3. [PubMed]